New publication reinforces the clinical benefits of Blue Light Cystoscopy demonstrating an improvement in detection of CIS
Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Blue-light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: histopathological characteristics and recurrence rates in a single center, prospective study” in BJUI Compass.
This week, clinical data from a prospective study conducted in the UK was published in BJUI Compass. The study was a single center, prospective study in 101 patients who underwent BLC between July 2017 - Nov 2020. It demonstrates how Blue Light Cystoscopy (BLC®) detected significantly more CIS (41.2% vs 11.8%, p=0.0491) compared to white light cystoscopy (WLC) with 5.8% upstaged to muscle invasive bladder cancer. The authors conclude that BLC with Hexvix provides superior detection and diagnosis of CIS in patients with previous white light cystoscopy.
The study publication was supported by Photocure ASA for the purpose of open access.
Read the full publication here: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.250